Twist inks collaboration deal with Adicet Bio

By The Science Advisory Board staff writers

Twist Bioscience and Adicet Bio will collaborate on the discovery and development of gamma delta T-cell cancer therapies.

The companies will develop immune cells with human chimeric antigen receptors and T-cell receptors aimed at disease-specific cell surface antigens, Twist said. Twist will contribute its proprietary single-chain fragment variable and VHH nanobody technologies from its library, which will support Adicet's discovery of new chimeric antigen receptors to generate novel gamma delta CAR T-cell products.

Adicet will pay Twist an upfront licensing fee as well as clinical and regulatory milestone payments and royalties.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?